NPI: 1124495239 · EAST NORRITON, PA 19401 · General Acute Care Hospital · NPI assigned 08/24/2015
Authorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
| Authorized Official | DOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL) |
| NPI Enumeration Date | 08/24/2015 |
Other providers sharing the same authorized official: DOAN, CHRISTOPHER
| Year | Claims | Total Paid |
|---|---|---|
| 2019 | 72 | $1K |
| 2020 | 3,466 | $318K |
| 2021 | 11,745 | $1.37M |
| 2022 | 6,610 | $1.16M |
| 2023 | 9,318 | $1.06M |
| 2024 | 7,246 | $583K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 6,252 | 5,907 | $1.50M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 4,792 | 4,574 | $1.08M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,345 | 4,155 | $872K |
| G0378 | Hospital observation service, per hour | 511 | 421 | $699K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1,467 | 1,366 | $179K |
| 96361 | Intravenous infusion, hydration; each additional hour | 687 | 629 | $50K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 325 | 296 | $44K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 161 | 154 | $18K |
| 80053 | Comprehensive metabolic panel | 3,242 | 2,857 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 48 | 43 | $7K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 76 | 76 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3,303 | 2,900 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 171 | 141 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | 271 | 240 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 296 | 269 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | 187 | 172 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 15 | 15 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 739 | 637 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 76 | 76 | $1K |
| 82550 | 972 | 865 | $1K | |
| 71045 | Radiologic examination, chest; single view | 647 | 589 | $1K |
| 84484 | 591 | 488 | $979.73 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 449 | 408 | $805.06 |
| 83690 | 584 | 545 | $525.52 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 54 | 52 | $454.22 |
| 84443 | Thyroid stimulating hormone (TSH) | 109 | 99 | $428.23 |
| 36415 | Collection of venous blood by venipuncture | 2,553 | 2,259 | $380.57 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 30 | 28 | $315.00 |
| 85730 | 159 | 134 | $218.03 | |
| 80320 | 125 | 107 | $211.68 | |
| 85610 | 184 | 156 | $178.19 | |
| 73630 | 27 | 24 | $165.39 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,979 | 1,522 | $160.71 |
| 84702 | 58 | 53 | $150.90 | |
| 81001 | 250 | 220 | $149.71 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 94 | 83 | $129.04 |
| 81003 | 239 | 218 | $112.25 | |
| 81025 | 191 | 161 | $100.48 | |
| 85379 | 52 | 41 | $53.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 742 | 655 | $47.87 |
| 80048 | Basic metabolic panel (calcium, ionized) | 13 | 12 | $37.44 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 28 | 26 | $25.78 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 600 | 523 | $17.36 |
| 82962 | 76 | 40 | $12.00 | |
| J3490 | Unclassified drugs | 505 | 322 | $5.97 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 16 | 13 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 14 | 13 | $0.00 |
| 84100 | 36 | 14 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 15 | 12 | $0.00 |
| 83735 | 36 | 14 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 33 | 27 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 17 | 14 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 15 | 13 | $0.00 |